英国布里斯托大学孵化的AI生物科技初创公司CellVoyant，近日宣布已完成760万英镑的种子轮融资。此轮融资由Octopus Ventures领投，Horizons Ventures、Air Street Capital和Verve Ventures参投。
CellVoyant公司致力于利用人工智能成像技术，帮助干细胞疗法开发商更有效地制造新疗法。干细胞疗法是一种具有广泛应用前景的治疗方法，可以用于治疗许多疾病，如心脏病、中风、糖尿病等。然而，干细胞疗法的研发过程复杂且成本高昂，需要大量的时间和资源。CellVoyant的技术可以帮助简化这一过程，降低研发成本，加速新疗法的上市。
据悉，本轮融资将用于加速CellVoyant的技术研发和市场拓展。该公司表示，将继续致力于开发创新技术，为干细胞疗法开发商提供更好的解决方案，以推动该领域的发展。
Title: AI biotech startup CellVoyant raises £7.6 million in seed funding
Keywords: AI biotech, CellVoyant, funding
News content:
The AI biotech startup CellVoyant, incubated by the University of Bristol in the UK, recently announced that it has completed a £7.6 million seed round of financing. This round of financing was led by Octopus Ventures, with participation from Horizons Ventures, Air Street Capital, and Verve Ventures.
CellVoyant is committed to using artificial intelligence imaging technology to help stem cell therapy developers manufacture new therapies more effectively. Stem cell therapy is a promising treatment method with a wide range of applications, such as treating heart disease, stroke, diabetes, and more. However, the research and development process of stem cell therapy is complex and costly, requiring a significant amount of time and resources. CellVoyant’s technology can help simplify this process, reduce research and development costs, and accelerate the launch of new therapies.
It is reported that the funds raised in this round will be used to accelerate the research and development and market expansion of CellVoyant’s technology. The company said it will continue to develop innovative technologies to provide better solutions for stem cell therapy developers, in order to promote the development of the field.
【来源】https://sifted.eu/articles/ai-biotech-cellvoyant-raise
Views: 1